Superworth

Fortrea price to free cash flow FTRE

Market value divided by free cash flow over the last twelve months, since 2024.

Today, Nov 2, 2026
11.4×
2-year median
8.2×
Against its 2-year history
84th
percentile: 0 is its lowest day, 100 its highest
2-year range
2.0× to 21.6×
Peer median
26.7×

Fortrea's price to free cash flow is 11.4× as of Nov 2, 2026.

That is above its 2-year median of 8.2×, higher than on 84% of days in the last 2 years.

Over that time it ranged from 2.0× in Apr 2025 to 21.6× in Jul 2024.

The median for 9 diagnostics and research stocks of a similar size is 26.7×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far11.4×6.6×12.9×
20253.4×2.0×7.7×
20247.7×6.5×21.6×

Against its peers

Companies in Medical - Diagnostics & Research nearest Fortrea's size, closest first, today.

CompanyPrice to free cash flow
FTREFortrea11.4×
VCYTVeracyte23.7×
CDNACareDxn/m
BLLNBillionToOne157×
LNTHLantheus16.9×
NRCNRC Health24.8×
CAICaris Life Sciences73.2×
BIOBio-Rad Laboratories27.7×
RVTYRevvity30.3×
MEDPMedpace25.6×
Peer median26.7×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Fortrea

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.